Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio” or the “Company”) announces that, on May 1, 2026, Assertio and Garda Therapeutics (“Garda”) entered into an Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which Garda has increased its offer to acquire all outstanding shares of Assertio to $21.80 per share in cash with no contingent value right. The increased offer represents a 21.1% premium to Garda’s original offer on April 8, 2026, and a 63.1% premium to the Company’s unaffected stock price on March 20, 2026 – the day before a significant share price and trading volume movement.
Read the full article: Assertio Announces Amended and Restated Merger Agreement with Garda Therapeutics //
Source: https://www.businesswire.com/news/home/20260504084803/en/Assertio-Announces-Amended-and-Restated-Merger-Agreement-with-Garda-Therapeutics